Hannah Weber, Co-Founder and Vice President of Strategy & Business Development at HOPO Therapeutics, presented an update on the development of investigational HOPO-101 at ConRad 2025, the Global Conference on Radiation Topics in Munich, Germany. Hosted by the Bundeswehr Institute of Radiobiology, the conference convenes civilian and military experts from around the world to share work in radiological preparedness, response, protection, and research.A summary of the event written by SEPR notes "One of the most notable updates was HOPO-101, a state-of-the-art chelator specifically designed for oral administration. Unlike DTPA—which requires intravenous or inhaled delivery—HOPO-101 has a high affinity for actinides and is formulated as tablets or capsules, greatly simplifying its use in mass casualty scenarios. At ConRad, it was confirmed that HOPO-101 has entered the early phases of clinical trials, generating strong interest as a potentially widely accessible antidote for nuclear incidents."
